Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 13, 2009

CombinatoRx Gains Preclinical B-Cell Cancer Therapy from Clinical Data in $252M Deal

  • Clinical Data licensed its preclinical candidate for B-cell cancers to CombinatoRx in a deal worth up to $252 million. CombinatoRx will initially develop this adenosine A2A.

    The $252 million will be paid with the achievement of clinical, regulatory, and commercial milestones. Clinical Data will also receive royalties on product sales. While CombinatoRx will be responsible for further development, Clinical Data retains a co-development option, which is exercisable after review of Phase IIa results. 

    Research has shown that a combination drug approach utilizing adenosine A2A agonists could be beneficial in the treatment of multiple myeloma, according to the firms. Initial results have demonstrated broad activity in multiple myeloma cell lines, synergy with multiple myeloma standard-of-care therapies, potent induction of apoptosis, as well as selectivity and safety with a broad therapeutic window over normal cells, they explain.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »